Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Jade Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
JBIO
Nasdaq
2836
jadebiosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Jade Biosciences, Inc.
Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week
- Jan 6th, 2026 5:07 am
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
- Jan 5th, 2026 5:00 am
Jade Biosciences Announces $45 Million Private Placement
- Dec 15th, 2025 5:00 am
Jade Biosciences (JBIO): Analyst Lauds Entry into Market
- Dec 10th, 2025 12:15 pm
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?
- Dec 4th, 2025 7:55 am
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock
- Nov 18th, 2025 10:00 am
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know
- Nov 18th, 2025 7:55 am
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Nov 13th, 2025 2:05 pm
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
- Nov 8th, 2025 9:00 am
Jade Biosciences to Participate in Upcoming Conferences
- Nov 3rd, 2025 5:00 am
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
- Oct 17th, 2025 2:05 pm
Jade Biosciences Raises $135 Million Through Private Placement
- Oct 7th, 2025 6:11 am
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
- Oct 7th, 2025 5:05 am
Jade Biosciences Announces $135 Million Private Placement
- Oct 7th, 2025 5:00 am
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
- Sep 2nd, 2025 5:00 am
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Aug 13th, 2025 2:05 pm
The early winner in the 'Dexit' war for corporate relocations: Nevada
- Jul 10th, 2025 2:00 am
Jade Biosciences to Participate in Two Upcoming Investor Conferences
- Jul 8th, 2025 5:00 am
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
- Jul 1st, 2025 5:00 am
2 Small-Cap Stocks Under $10 to Buy With Big Potential
- Jun 24th, 2025 5:30 am
Scroll